Intrinsic Therapeutics Announces Changes in CMS’ 2025 Final Rule for Bone Anchored Annular Closure Resulting in Improved Payment for Hospital Outpatient and ASCs

BOSTON, Nov. 12, 2024 /PRNewswire/ — Intrinsic Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81% with its Barricaid Annular Closure Device,…